Department of Microbiology, National Reference Centre for toxigenic corynebacteria, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium.
Respiratory and Vaccine Preventable Bacteria Reference Unit, Public Health England - National Infection Service, London, UK.
J Med Microbiol. 2019 Oct;68(10):1517-1525. doi: 10.1099/jmm.0.001039.
In Western Europe, the incidence of both respiratory and cutaneous diphtheria, caused by toxin-producing , or , has been low over the past few decades thanks to the use of an effective vaccine and a high level of vaccination coverage. However, the disease has still not been eradicated and continues to occur in all of Europe. In order to prevent sequelae or a fatal outcome, diphtheria antitoxin (DAT) should be administered to suspected diphtheria patients as soon as possible, but economic factors and issues concerning regulations have led to poor availability of DAT in many countries. The European Centre for Disease Prevention and Control and World Health Organization have called for European Union-wide solutions to this DAT-shortage. In order to illustrate the importance of these efforts and underline the need for continued diphtheria surveillance, we present data on all registered cases of toxigenic and non-toxigenic , and in Belgium during the past decade, up to and including 2017.
在过去几十年中，由于使用了有效的疫苗和高水平的疫苗接种覆盖率，西欧由产毒或非产毒引起的呼吸道和皮肤白喉的发病率一直较低。然而，这种疾病尚未被根除，仍在欧洲所有地区发生。为了预防后遗症或致命后果，应尽快向疑似白喉患者施用白喉抗毒素（DAT），但经济因素和有关法规问题导致许多国家的 DAT 供应不足。欧洲疾病预防控制中心和世界卫生组织呼吁欧盟范围内对此类 DAT 短缺问题采取解决方案。为了说明这些努力的重要性，并强调继续进行白喉监测的必要性，我们展示了过去十年中（截至 2017 年）在比利时登记的所有产毒和非产毒以及的病例数据。
